Why ICON is celebrating its first Inclusion Day
Inclusion Day is an opportunity for us to come together in ICON as an organisation to think about the choices we make to further inclusion and diversity.
Irritable Bowel Disease (IBD): A patient’s perspective
Finding appreciation in the experience and treatment of IBD as a life-changing condition.
My Clinical Research story – Jeslyne Margrette Isaac
ICON's Jeslyne Margrette Isaac shares their personal experience with clinical trials.
My Clinical Research story – Lisa Linn
ICON's Lisa Linn shares their personal experience with clinical trials.
My Clinical Research story – Jill Doherty
ICON's Jill Doherty shares their personal experience with clinical trials.
My Clinical Research story – Ellen Dalbo
ICON's Ellen Dalbo shares their personal experience with clinical trials.
Clinical Trials Day – Employee Testimonials
ICON's Ben Prabhu, Amber Hallenborg, Shannon Jonietz, Rebekah Nolan, Kim Pope, Agustina Mazza, Linsey Barone, Catherine Bliss, Robyn Vancil, and Louisa Roberts share their personal experience with clinical trials.
How joint venture models can boost Japan’s pharmaceutical industry
Japan is the third-largest consumer of ethical drugs and the world’s third-largest economy; therefore, it is an important development centre for new medicines. However, there are various cultural and economic challenges in Japan that make it difficult to manage a fixed workforce against a variable portfolio of clinical research.
NICE guidance on real-world evidence to usher innovative treatments
NICE published new guidance to give patients early access to innovative treatments by allowing greater flexibility considering a broader evidence base, making it easier for innovative and promising treatments to reach the patient incorporating the usage of real-world evidence.
Sharing my Down syndrome story - Beverly Romero
Beverly Romero tells the story of her son Oliver.
Progressive IVDR rollout made official
In the fall of 2020, the European Commission issued a proposal to modify the implementation timeline for the new In Vitro Diagnostic Medical Devices Regulation (IVDR). Now, as of 15 December 2021, the European Parliament and the European Council have adopted this proposal, making the suggested progressive IVDR rollout timeline official.
Combatting AMR with new tools to diagnose and treat infectious disease
The employment of antimicrobials to fight previously devastating microbial diseases, such as tuberculosis, meningitis and pneumonia has been a transformative medical achievement.
Camaraderie and collaboration – what sets ICON apart
ICON was recently named one of the World’s Best Employers for 2021 by global media company Forbes. This recognition is solely the result of employees’ on-the-job experiences and firsthand feedback.
EC proposes extended transition period for IVDR compliance
The European Commission has issued a proposal for a modified rollout of the new In Vitro Diagnostic Regulation (IVDR).
Diverse clinical research starts with the healthcare workforce
Diversity initiatives are a hallmark of clinical research. From US Food and Drug Administration (FDA)-penned guidance and pharma initiatives.
How we can continue building a diverse, equal, and inclusive industry
Workplace diversity encourages collaboration and innovation – every team member brings their own unique backgrounds, experiences, and perspectives at ICON.
Navigating cardiovascular clinical trial adjudication during a respiratory pandemic
COVID-19 disrupted clinical trials across all indications. Patient enrolment, participation, data collection, and more was forced to adapt to the challenges of this virus.
The impact of the COVID-19 pandemic on mental health
Learn how the ongoing state of the COVID-19 pandemic has affected the global mental health crisis.
ICON Joins UNICEF Corporate Vaccine Alliance
ICON is one of seven leading Irish companies that just endorsed an open letter urging fellow corporate leaders to join the UNICEF Corporate Vaccine Alliance.
Rare disease patients and advocates drive change in public policy
Learn how patient advocacy organisations and rare disease communities are driving change in US public policy to make safe and effective treatment options available to all patients.